Frontage Holdings Corporation (01521.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.8x

Market Cap

HKD 2.63B

MomentumView details →

1D Return

−0.38%

YTD Return

+29.50%

RSI (14)

61.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.8x

Market Cap

HKD 2.63B

RSI (14)

61.9

MomentumView details →

1D Return

−0.38%

YTD Return

+29.50%

ProfitabilityView details →

Gross Margin

26.74%

Net Margin

2.72%

EBITDA Margin

17.42%

ROE (TTM)

4.07%

ROA (TTM)

2.49%

Asset Turnover

0.95x

GrowthView details →

Revenue YoY

+2.15%

EPS YoY

−38.05%

FCF YoY

+78.42%

Revenue CAGR 3Y

+0.84%

EPS CAGR 3Y

−35.38%

EBITDA YoY

+4.05%

EarningsView details →

EPS (Actual)

HKD 0.05

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

9.32%

Capital & dividendView details →

Debt/Equity

0.40x

Current Ratio

1.41x

Quick Ratio

1.33x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

530.96M

Net Income (TTM)

14.44M

Op. CF (TTM)

—

Next earningsMar 29, 2027 →

Latest newsMore news →

Frontage Holdings reported interim results for the six months ended June 2026, with revenue of $148 million, up 17.1% year-on-year, and net profit attributable to owners of $6.755 million, up 1.3 times year-on-year.8d ago

Similar companies

Clover Biopharmaceuticals, Ltd.02197.HK Viridian Therapeutics, Inc.VRDN Vera Therapeutics, Inc.VERA Beijing Luzhu Biotechnology Co., Ltd.02480.HK BioCryst Pharmaceuticals, Inc.BCRX Precigen, Inc.PGEN Find similar companies →

Latest newsMore news →

Frontage Holdings reported interim results for the six months ended June 2026, with revenue of $148 million, up 17.1% year-on-year, and net profit attributable to owners of $6.755 million, up 1.3 times year-on-year.8d ago